Literatur
- 1 Oertel W H, Reichmann H. Parkinson-Syndrome: Diagnostik und Therapie. In: Diener H C,
Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie.. Stuttgart: Thieme;
2008: 82-112
- 2
Braak H, Del Tredici K.
Pathophysiologie des sporadischen Morbus Parkinson.
Fortschr Neurol Psychiat.
2010;
78 (Suppl 1)
2-4
- 3
Wojtecki L, Südmeyer M, Schnitzler A.
Current Treatment of Parkinson’s disease.
Dtsch Arztebl.
2007;
104
2513-2522
- 4
LeWitt P A.
Levodopa for the treatment of Parkinson’s disease.
N Engl J Med.
2008;
359
2468-2476
- 5
Koller W C, Hutton J T, Tolosa E et al.
Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized
multicenter study.
Neurology.
1999;
53
1012-1019
- 6
Stocchi F, Rascol O, Kieburtz K et al.
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson
disease – the STRIDE-PD study.
Ann Neurol.
2010;
68
18-27
- 7
Parkinson Study Group CALM Cohort Investigators .
Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease.
Arch Neurol.
2009;
66
563-570
- 8
Schade R, Andersohn F, Suissa S et al.
Dopamine agonists and the risk of cardiac-valve regurgitation.
N Engl J Med.
2007;
356
29-38
- 9
Zanettini R, Antonini A, Gatto G et al.
Valvular heart disease and the use of dopamine agonists for Parkinson’s disease.
N Engl J Med.
2007;
356
39-46
- 10
Onofrj M, Bonanni L, De Angelis M V et al.
Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole
prolonged-release studies.
Parkinsonism Relat Disord.
2009;
15 (Suppl 4)
85-92
- 11
Fahn S, Shoulson I, Kieburtz K et al.
Levodopa and the progression of Parkinson’s disease.
N Engl J Med.
2004;
351
2498-2508
- 12
Schulz J B, Gerlach M, Gille G et al.
Basic science in Parkinson’s disease: its impact on clinical practice.
J Neurol.
2011;
258 (Suppl 2)
299-306
- 13
Wallace B A, Ashkan K, Heise C E et al.
Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of
the subthalamic nucleus in MPTP-treated monkeys.
Brain.
2007;
130
2129-2145
- 14
Rascol O.
„Disease-modification“ trials in Parkinson disease: target populations, endpoints
and study design.
Neurology.
2009;
72 (Suppl 2)
51-58
- 15
Olanow C W, Rascol O, Hauser R et al.
A double-blind, delayed-start trial of rasagiline in Parkinson’s disease.
N Engl J Med.
2009;
361
1268-1278
- 16
Schapira A H, Albrecht S, Barone P et al.
Rationale for delayed-start study of pramipexole in Parkinson’s disease: the PROUD
study.
Mov Disord.
2010;
25
1627-1632
- 17
Rascol O, Fitzer-Attas C F, Hauser R et al.
A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO
study): prespecified and post-hoc analyses of the need for additional therapies, changes
in UPDRS scores, and non-motor outcomes.
Lancet Neurol.
2011;
10
415-423
- 18
Kostic V, Przedborski S, Flaster E et al.
Early development of levodopa-induced dyskinesias and response fluctuations in young-onset
Parkinson’s disease.
Neurology.
1991;
41
202-205
- 19
Entacaponeto Tolcapone Switch Study Investigators .
Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled
trial in advanced Parkinson’s disease.
Mov Disord.
2007;
22
14-19
- 20
Rascol O, Brooks D J, Melamed E et al.
Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor
fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once
daily, study): a randomised, double-blind, parallel-group trial.
Lancet.
2005;
365
947-954
- 21
Wolf E, Seppi K, Katzenschlager R et al.
Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease.
Mov Disord.
2010;
25
1357-1363
- 22
Stocchi F, Giorgi L, Hunter B et al.
PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s
disease.
Mov Disord.
2011;
26
1259-1265
- 23
Deuschl G, Schade-Brittinger C, Krack P et al.
A randomized trial of deep-brain stimulation for Parkinson’s disease.
N Engl J Med.
2006;
355
896-908
- 24
Williams A, Gill S, Varma T et al.
Deep brain stimulation plus best medical therapy versus best medical therapy alone
for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial.
Lancet Neurol.
2010;
9
581-591
- 25
Follett K A, Weaver F M, Stern M et al.
Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease.
N Engl J Med.
2010;
362
2077-2091
- 26
Fasano A, Romito L M, Daniele A et al.
Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic
implants.
Brain.
2010;
133
2664-2676
- 27
Clarke C E, Worth P, Grosset D et al.
Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation
in advanced Parkinson’s disease.
Parkinsonism Relat Disord.
2009;
15
728-741
- 28
Devos D for the French DUODOPA Study Group .
Patient profile, indications, efficacy and safety of duodenal levodopa infusion in
advanced Parkinson’s disease.
Mov Disord.
2009;
24
993-1000
- 29
De Gaspari D, Siri C, Cilia A L et al.
Clinical and neuropsychological follow up at 12 months in patients with complicated
Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation
of the subthalamic nucleus.
J Neurol Neurosurg Psychiatry.
2006;
77
450-453
- 30
Ebersbach G, Ebersbach A, Edler D et al.
Comparing exercise in Parkinson’s disease – the Berlin LSVT®BIG study.
Mov Disord.
2010;
25
1902-1908
- 31
Ramig L O, Sapir S, Countryman S et al.
Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow
up.
J Neurol Neurosurg Psychiatry.
2001;
71
493-498
- 32
Menza M, Dobkin R D, Marin H et al.
A controlled trial of antidepressants in patients with Parkinson disease and depression.
Neurology.
2009;
72
886-892
- 33
Timmermann L, Maier F, Eggers C et al.
Demenz bei Morbus Parkinson: Sinnvolle Diagnostik und rationale Therapie.
Fortschr Neurol Psychiat.
2010;
78
513-518
- 34
Weintraub D, Koester J, Potenza M N et al.
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
Arch Neurol.
2010;
67
589-595
Dr. Martin Südmeyer
Neurologische Klinik – Bewegungsstörungen und Neuromodulation, Medizinische Fakultät,
UKD
Moorenstr. 5
40225 Düsseldorf
eMail: martin.suedmeyer@uni-duesseldorf.de
